ASX healthcare stocks riding on their accomplishments
From the world’s first MRI-guided heart procedure to rapid global expansion in regenerative medicine, these ASX healthcare stocks are entering an important growth phase and are worth tracking closely
Imricor Medical Systems Inc (ASX: IMR)
has recently achieved a major medical milestone by completing the world’s first ischemic ventricular tachycardia (VT) ablation under real-time MRI guidance at Amsterdam UMC.
This procedure marks the first time a complex VT case has been done fully inside an MRI lab and it represents a huge step forward in cardiac treatment technology.
After completion, the patient came out non-inducible for VT which shows the massive success.
The company finished the quarter with about US$38.3 million in cash and US$7.5 million in short-term investments which gives it a strong cash runway as it expands.
Orthocell Limited (ASX: OCC)
is stepping into a major growth phase as it scales its breakthrough regenerative medicine portfolio across key global markets.
The recent rollout of Remplir continues to accelerate worldwide as Hong Kong recently marked its first surgical case and product launch at the Hong Kong Orthopaedic Association Congress, supported by local distributor MontsMed.
Quarterly revenue hit $2.75 million in the June period and momentum is building further into FY26 as US adoption ramps up
Orthocell remains in a very strong financial position with over $50 million in cash, no debt and no royalties payable on its products.
All manufacturing is done in-house at its ISO-certified Perth facility which supports global supply and helps preserve margins.
Botanix Pharmaceuticals Limited (ASX: BOT)
launched its first commercial product called Sofdra which treats excessive underarm sweating and this product became the first FDA-approved treatment for this condition and early demand has been great with fast prescription growth in its first quarters on the market.
Sofdra’s net revenue has increased from $4.3 million in Q4 FY25 to $7.1 million in Q1 FY26 which is an increase of 65%
Total prescriptions grew 50% from 13,647 in Q4 FY25 to 20,418 in Q1 FY26.
The balance sheet looks solid with $49.2 million in cash at the end of quarter which gives enough room to keep expanding commercial reach without slowing down.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
